Stay updated with breaking news from Therapy Training Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine...
/PRNewswire/ -- The non-profit Multidisciplinary Association of Psychedelic Studies (MAPS) and MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned...
/PRNewswire/ -- The non-profit Multidisciplinary Association of Psychedelic Studies (MAPS) and MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned...
The FDA recently approved of therapists taking MDMA to understand the psychedelic drug for Phase 1 trials in an effort to prove its medical efficacy.
Psyched: MindMed And Compass Q1 Earnings, FDA Approves Therapists Taking MDMA, Wesana Health Goes Public Compass Pathways (NASDAQ:CMPS) and MindMed (NASDAQ:MNMD) remain the only two companies in psychedelics to reach a major U.S. stock exchange. Both companies presented net losses associated with R&D expenses, as entities in the space race towards gaining ground in a sector that still hasn’t reached early maturity or profitability. Both companies presented strong cash positions to advance their research pipelines. Compass, Pressing On Psilocybin: Compass highlighted the issuing of two new ...